Editor's Note: This is a compilation of our most-read stories of 2022. Fierce Biotech is on a publishing break for the Christmas holidays. We'll be back in your inboxes on Tuesday, January 3. Happy Holidays!
Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The goal suggests the U.S. could join the U.K. on the list of countries to authorize the vaccine in the first half of the year.
We discuss how small and mid-sized biotechs can succeed at the start of their first clinical trials. We go in-depth about biotech industry innovation and how companies are bringing value to the industry currently, and how they can add value if they aren’t already.
New research out of Indiana University suggests vitamin B3, also known as niacin, could have the potential to treat Alzheimer's. The scientists found improved working memory and a reduction in amyloid plaques among mice treated with a prescription form of the supplement.
Moderna is adding two more vaccine programs to its roster: a combination respiratory candidate and a shot targeting all four endemic human coronaviruses that cause the common cold.
Moderna has started dosing in a phase 1 trial for the second of two HIV vaccines it's developing, showing that it's all gas, no breaks for the mRNA-focused biotech as it races Excision BioTherapeutics for a breakthrough HIV therapy. The start of dosing comes roughly six weeks after it launched human trials for its first vaccine.
All the biopharma world is talking about right now is M&A. Who’s going to buy? How much are they willing to spend? Who’s going to get bought? Here are our predictions.
At least 30 biopharmas have announced layoffs since September 2021, and the wave is likely to continue as thousands of startups struggle to stay above the competition.
The second arm of Moderna’s omicron booster trial has gotten underway with a first patient dosed in the phase 2 study testing a variant-specific vaccine against COVID-19.
The unstoppable march of Eli Lilly’s tirzepatide continues. Having previously shown the dual GIP/GLP-1 agonist reduces the weight of people with diabetes, Lilly has now delivered a hit in its first phase 3 pure play obesity trial, putting Novo Nordisk’s Wegovy on notice that a serious challenger may be on the horizon.
By Kyle LaHucik,Annalee Armstrong,Max Bayer,Eric Sagonowsky,Kevin Dunleavy
CEOs at dozens of biotechs and investors from the industry's leading venture firms urged their global business counterparts to "disengage from Russian industry" over the weekend.
This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week.
Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions.
Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.
Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.
